[go: up one dir, main page]

MX2019015352A - Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1). - Google Patents

Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1).

Info

Publication number
MX2019015352A
MX2019015352A MX2019015352A MX2019015352A MX2019015352A MX 2019015352 A MX2019015352 A MX 2019015352A MX 2019015352 A MX2019015352 A MX 2019015352A MX 2019015352 A MX2019015352 A MX 2019015352A MX 2019015352 A MX2019015352 A MX 2019015352A
Authority
MX
Mexico
Prior art keywords
cells
car
ror1 car
receptor
ror1
Prior art date
Application number
MX2019015352A
Other languages
English (en)
Inventor
Amit Nathwani
Satyen Gohil
Peruta Marco Della
Original Assignee
Ucl Business Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucl Business Ltd filed Critical Ucl Business Ltd
Publication of MX2019015352A publication Critical patent/MX2019015352A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/31—Chimeric antigen receptors [CAR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/421—Immunoglobulin superfamily
    • A61K40/4211—CD19 or B4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4256—Tumor associated carbohydrates
    • A61K40/4258—Gangliosides, e.g. GM2, GD2 or GD3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70517—CD8
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/70521—CD28, CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)

Abstract

Se describe un receptor de antígeno quimérico (CAR) el cual comprende un dominio de unión a antígeno el cual se une selectivamente al receptor 1 huérfano tipo receptor de tirosina cinasa (ROR1) y su uso. También se describe un linfocito T que comprende el CAR y su uso en el tratamiento del cáncer.
MX2019015352A 2017-07-05 2018-07-05 Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1). MX2019015352A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1710836.6A GB201710836D0 (en) 2017-07-05 2017-07-05 ROR1 Car T-Cells
PCT/GB2018/051915 WO2019008378A1 (en) 2017-07-05 2018-07-05 Ror1 car t-cells

Publications (1)

Publication Number Publication Date
MX2019015352A true MX2019015352A (es) 2020-07-20

Family

ID=59592474

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019015352A MX2019015352A (es) 2017-07-05 2018-07-05 Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1).

Country Status (9)

Country Link
US (1) US11723925B2 (es)
EP (1) EP3649150B1 (es)
JP (1) JP7179030B2 (es)
CN (1) CN110997709B (es)
AU (1) AU2018295478A1 (es)
CA (1) CA3068197A1 (es)
GB (1) GB201710836D0 (es)
MX (1) MX2019015352A (es)
WO (1) WO2019008378A1 (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
CN108441505B (zh) * 2018-05-28 2023-07-07 上海恒润达生生物科技股份有限公司 一种靶向ror1的嵌合抗原受体及其用途
CN114929751B (zh) * 2019-09-27 2024-11-05 南京艾美斐生物医药科技有限公司 Ror1特异性嵌合抗原受体及其治疗应用
BR112023002895A2 (pt) * 2020-08-24 2023-03-21 Epimab Biotherapeutics Hk Ltd Anticorpos anti-ror1 e proteínas de ligação biespecíficas relacionadas
US12144827B2 (en) 2021-02-25 2024-11-19 Lyell Immunopharma, Inc. ROR1 targeting chimeric antigen receptor
IL312204A (en) 2021-10-28 2024-06-01 Lyell Immunopharma Inc Methods for culturing cells expressing ror1-binding protein
CN114133457B (zh) * 2021-12-08 2022-08-19 郑州源创吉因实业有限公司 一种靶向ror1和cd33的双特异性嵌合抗原受体(car)及其应用
CN118974090A (zh) * 2022-04-02 2024-11-15 山东先声生物制药有限公司 抗ror1的抗体及其用途
WO2024064958A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
WO2024064952A1 (en) 2022-09-23 2024-03-28 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells overexpressing c-jun
WO2024077174A1 (en) 2022-10-05 2024-04-11 Lyell Immunopharma, Inc. Methods for culturing nr4a-deficient cells
CN116903740B (zh) * 2023-04-21 2024-04-30 星奕昂(上海)生物科技有限公司 靶向ror1的抗体及其应用
WO2025006880A1 (en) * 2023-06-29 2025-01-02 Caribou Biosciences, Inc. Diagnostic and therapeutic methods for use with ror1 antagonists
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
WO2025217398A1 (en) 2024-04-10 2025-10-16 Lyell Immunopharma, Inc. Methods for culturing cells with improved culture medium
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0920798A (ja) * 1995-07-11 1997-01-21 Asahi Chem Ind Co Ltd ヒト抗ＨＢｓ抗体
KR20120125634A (ko) 2003-10-16 2012-11-16 마이크로메트 에이지 다중특이적 탈면역화된 ｃｄ3-바인더
PT1871805T (pt) * 2005-02-07 2019-12-02 Roche Glycart Ag Moléculas de ligação a antigénios que se ligam ao rfce, vetores que as codificam e as suas utilizações
WO2007146957A2 (en) 2006-06-13 2007-12-21 Irm Llc Ror1 as a therapeutic target for lung cancer
EP2421899B1 (en) 2009-04-23 2016-06-08 The United States of America, as represented by The Secretary, Department of Health and Human Services Anti-human ror1 antibodies
NZ621170A (en) * 2009-05-13 2015-08-28 Genzyme Corp Anti-human cd52 immunoglobulins
WO2011054007A1 (en) 2009-11-02 2011-05-05 Oxford Biotherapeutics Ltd. Ror1 as therapeutic and diagnostic target
WO2011079902A2 (en) 2009-12-18 2011-07-07 Biolnvent International Ab Biological materials and uses thereof
EP3828205A1 (en) 2010-10-01 2021-06-02 Oxford BioTherapeutics Ltd Anti-ror1 antibodies
EP2646469B1 (en) 2010-12-01 2017-11-01 The United States of America, as represented by The Secretary, Department of Health and Human Services Chimeric rabbit/human ror1 antibodies
GB201020995D0 (en) 2010-12-10 2011-01-26 Bioinvent Int Ab Biological materials and uses thereof
CA3027071A1 (en) 2011-01-14 2013-07-19 The Regents Of The University Of California Therapeutic antibodies against ror-1 protein and methods for use of same
IL293944A (en) 2012-08-20 2022-08-01 Hutchinson Fred Cancer Res Method and preparations for cellular immunotherapy
ES2702315T3 (es) 2012-08-24 2019-02-28 Univ California Anticuerpos y vacunas para su uso en tratar cánceres ROR1 e inhibir metástasis
WO2014153164A1 (en) * 2013-03-14 2014-09-25 The California Institute For Biomedical Research Targeting agent antibody conjugates and uses thereof
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
TN2016000525A1 (en) 2014-05-29 2018-04-04 Macrogenics Inc Tri-specific binding molecules and methods of use thereof
EP3453406B1 (en) * 2014-07-29 2021-04-14 Cellectis Ror1 (ntrkr1) specific chimeric antigen receptors for cancer immunotherapy
US10544201B2 (en) 2014-07-31 2020-01-28 Cellectis ROR1 specific multi-chain chimeric antigen receptor
CA2960466C (en) * 2014-09-08 2023-09-05 National Cancer Center Cancer cell-specific antibody, anticancer drug and cancer testing method
CA2963696A1 (en) 2014-10-09 2016-04-14 Engmab Ag Bispecific antibodies against cd3epsilon and ror1 for use in the treatment of ovarian cancer
AU2015329965A1 (en) 2014-10-09 2017-04-27 Engmab Sàrl Bispecific antibodies against CD3epsilon and ROR1
WO2016094873A2 (en) 2014-12-12 2016-06-16 Emergent Product Development Seattle, Llc Receptor tyrosine kinase-like orphan receptor 1 binding proteins and related compositions and methods
CA2972597A1 (en) * 2014-12-29 2016-07-07 Novartis Ag Methods of making chimeric antigen receptor-expressing cells
AR103442A1 (es) 2015-01-16 2017-05-10 Juno Therapeutics Inc Anticuerpos y receptores de antígenos quiméricos específicos de ror1
BR112017016428B1 (pt) 2015-02-02 2023-10-24 Kancera Ab Composto ou sal farmaceuticamente aceitável, composição farmacêutica, e, uso de um composto ou sal farmaceuticamente aceitável
MX388174B (es) * 2015-04-14 2025-03-19 Academia Sinica Anticuerpo anti-vegfr2 humano para terapia del cancer anti-angiogenica y dirigida
US20180147271A1 (en) * 2015-05-18 2018-05-31 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
JP2018524284A (ja) 2015-05-18 2018-08-30 ユーリカ セラピューティックス， インコーポレイテッド 抗ｒｏｒ１抗体
HK1254836A1 (zh) 2015-10-30 2019-07-26 Nbe-Therapeutics Ag 抗-ror1抗体
BR112018014615A2 (pt) 2016-01-20 2018-12-11 The Scripps Research Institute composições de anticorpo para ror1 e métodos relacionados
US20170210799A1 (en) 2016-01-22 2017-07-27 Janssen Biotech, Inc. Anti-ror1, antibodies, ror1 x cd3 bispecific antibodies, and methods of using the same
AR108034A1 (es) 2016-02-17 2018-07-11 Macrogenics Inc Moléculas de unión a ror1, y métodos de uso de las mismas
WO2017156479A1 (en) 2016-03-11 2017-09-14 Bluebird Bio, Inc. Ror1 chimeric antigen receptors
CN109563092B (zh) 2016-07-11 2021-09-14 坎塞拉有限公司 可用作哺乳动物酪氨酸激酶ror1活性的抑制剂的2-苯基咪唑并[4,5-b]吡啶-7-胺衍生物
WO2018119314A1 (en) 2016-12-22 2018-06-28 Ardeagen Corporation Anti-ror1 antibody and conjugates thereof
JP2020521448A (ja) 2017-05-23 2020-07-27 ドラゴンフライ セラピューティクス， インコーポレイテッド Ｎｋｇ２ｄ、ｃｄ１６、およびｒｏｒ１またはｒｏｒ２に結合するタンパク質
KR102736878B1 (ko) 2017-06-23 2024-12-05 벨로스바이오 인코포레이티드 Ror1 항체 면역접합체
JP7323513B2 (ja) 2017-06-25 2023-08-08 システィミューン， インク． 抗４－１ｂｂ抗体とその作製及び使用方法
GB201710835D0 (en) * 2017-07-05 2017-08-16 Ucl Business Plc ROR1 Antibodies
EP3655435A1 (en) 2017-07-20 2020-05-27 NBE-Therapeutics AG Multispecific antibody product that binds to different ror1 epitopes
SG11202000846WA (en) 2017-08-07 2020-02-27 Nbe Therapeutics Ag Anthracycline-based antibody drug conjugates having high in vivo tolerability
WO2019090110A1 (en) 2017-11-03 2019-05-09 Lentigen Technology, Inc. Compositions and methods for treating cancer with anti-ror1 immunotherapy
GB201721802D0 (en) 2017-12-22 2018-02-07 Almac Discovery Ltd Ror1-specific antigen binding molecules
WO2019225777A1 (ko) 2018-05-23 2019-11-28 에이비엘바이오 주식회사 항-ror1 항체 및 그 용도
US11723926B2 (en) * 2019-09-27 2023-08-15 Starkage Therapeutics Senescent cell-associated antigen-binding domains, antibodies and chimeric antigen receptors comprising the same, and uses thereof

Also Published As

Publication number Publication date
AU2018295478A1 (en) 2020-01-16
WO2019008378A1 (en) 2019-01-10
JP7179030B2 (ja) 2022-11-28
GB201710836D0 (en) 2017-08-16
CA3068197A1 (en) 2019-01-10
EP3649150B1 (en) 2024-06-26
CN110997709A (zh) 2020-04-10
CN110997709B (zh) 2023-12-05
US20200405759A1 (en) 2020-12-31
US11723925B2 (en) 2023-08-15
EP3649150A1 (en) 2020-05-13
JP2020529838A (ja) 2020-10-15

Similar Documents

Publication Publication Date Title
MX2019015352A (es) Linfocitos t con receptor de antigeno quimerico (car) para receptor 1 huerfano tipo receptor de tirosina cinasa (ror 1).
PH12018500815A1 (en) Antibody conjugates comprising toll-like receptor agonist
PH12020551689A1 (en) Her2-targeting antigen binding molecules comprising 4-1bbl
MX2017001599A (es) Anticuerpos novedosos y sus usos.
MX2017004311A (es) Anticuerpos del receptor del factor de necrosis tumoral inducido por glucocorticoide (gitr) y metodos de uso de los mismos.
CL2018000458A1 (es) Conjugados anticuerpo anti-dll3-fármaco y métodos de uso
ZA202101495B (en) Chimeric antigen receptor
NZ762750A (en) Anti-hla-a2 antibodies and methods of using the same
MX2025002661A (es) Composiciones anti-cd24 y usos de las mismas
MX2023002588A (es) Anticuerpos anti-tgf-beta y su uso.
MX2019015348A (es) Anticuerpos contra receptor 1 huerfano tipo receptor de tirosina cinasa (ror1).
PH12018500766A1 (en) Bispecific antibodies with tetravalency for a costimulatory tnf receptor
PH12018500861A1 (en) Antibody/t-cell receptor chimeric constructs and uses thereof
WO2015050959A8 (en) Anti-kit antibodies and methods of use thereof
MX2019012811A (es) Conjugados de anticuerpos que comprenden agonista del receptor de tipo toll y terapias de combinacion.
SA517381703B1 (ar) C10orf54 - أجسام مضادة لـ واستخداماتها
NZ604003A (en) Monoclonal antibodies against her2
EA202090204A1 (ru) Анти-cd137 антитела
MY188362A (en) Chimeric antigen receptors based on single-domain antibodies and methods of use thereof
MX392069B (es) Anticuerpos del ligando similar al factor de necrosis tumoral 1a (tl1a) y usos de los mismos.
PH12020550908A1 (en) Anti-cxcr5 antibodies and compositions and uses thereof
MX2017002862A (es) Nuevos anticuerpos anti-mfi2 y metodos de uso.
PH12020551968A1 (en) Anti-sez6 antibody drug conjugates and methods of use
PH12019501605A1 (en) Glucagon receptor binding proteins and methods of use thereof
MX2024003627A (es) Anticuerpos contra el receptor del factor de necrosis tumoral inducido por glucocorticoides (gitr) y sus metodos de uso.